Your browser doesn't support javascript.
loading
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
Chen, Rong; Gultyaev, Dmitry; Lister, Johanna; Han, Rong; Hu, Nan; Malacan, Jean; Solms, Alexander; Vashi, Parth; O'Hara, Jamie; Hu, Shanlian.
  • Chen R; Hematology Department, Chengdu Third People's Hospital, Chengdu, China.
  • Gultyaev D; Certara USA, Inc, Lorrach, Germany.
  • Lister J; Formerly Certara USA, Inc, Lorrach, Germany.
  • Han R; Medical Affairs, Pharmaceuticals, Bayer Healthcare Company. Ltd, Beijing, China.
  • Hu N; Medical Affairs, Pharmaceuticals, Bayer Healthcare Company. Ltd, Beijing, China.
  • Malacan J; Global Market Access Hematology, Bayer Consumer Care AG, Peter Merian-Strasse 84, CH-4002, Basel, Switzerland. jean.malacan@bayer.com.
  • Solms A; Clinical Pharmacometrics, Bayer AG, Berlin, Germany.
  • Vashi P; Formerly at US Data Generation and Observational Studies, Bayer Corporation, Whippany, NJ, USA.
  • O'Hara J; HCD Economics, Daresbury, UK.
  • Hu S; School of Public Health, Fudan University, Shanghai, China.
BMC Med Res Methodol ; 22(1): 215, 2022 08 05.
Article en En | MEDLINE | ID: mdl-35931967
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Factor VIII / Hemofilia A Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Factor VIII / Hemofilia A Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article